Yuto Yasuda

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Topics

Small Cell Lung Cancer

Tyrosine Kinase

Respiratory Syndrome Coronavirus

Top Venues

Infectious disease reports

Scientific reports

Nature communications

This page only lists publications with an associated author ORCID identifier.

Publications

Yuto Yasuda, Lu Wang, Pasquale Chitano, Chun Y Seow
Rho-Kinase Inhibition of Active Force and Passive Tension in Airway Smooth Muscle: A Strategy for Treating Airway Hyperresponsiveness in Asthma. Biology 13 (2) (2024)
Yuto Yasuda, Lu Wang, Pasquale Chitano, Chun Y Seow
Rho-Kinase Inhibition of Active Force and Passive Tension in Airway Smooth Muscle: A Strategy for Treating Airway Hyperresponsiveness in Asthma. Biology 13 (2) (2024)
Yuto Yasuda, Lu Wang, Pasquale Chitano, Chun Y Seow
Rho-Kinase Inhibition of Active Force and Passive Tension in Airway Smooth Muscle: A Strategy for Treating Airway Hyperresponsiveness in Asthma. Biology 13 (2) (2024)
Yuto Yasuda, Satoru Mutsuo, Motoaki Hamada, Kazuo Murai, Yutaka Hirayama, Kiyoshi Uemasu, Soichi Arasawa, Daisuke Iwashima, Ken-Ichi Takahashi
Aluminium Gauze Reduces SARS-CoV-2 Viral Load in Non-Woven Masks Worn by Patients with COVID-19. Infectious disease reports 14 (2) (2022)
Kana Fujimoto, Satoru Mutsuo, Yuto Yasuda, Soichi Arasawa, Noriyuki Tashima, Daisuke Iwashima, Ken-Ichi Takahashi
Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants. Infectious disease reports 14 (6) (2022)
Kana Fujimoto, Satoru Mutsuo, Yuto Yasuda, Soichi Arasawa, Noriyuki Tashima, Daisuke Iwashima, Ken-Ichi Takahashi
Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants. Infectious disease reports 14 (6) (2022)
Kana Fujimoto, Satoru Mutsuo, Yuto Yasuda, Soichi Arasawa, Noriyuki Tashima, Daisuke Iwashima, Ken-Ichi Takahashi
Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants. Infectious disease reports 14 (6) (2022)
Kana Fujimoto, Satoru Mutsuo, Yuto Yasuda, Soichi Arasawa, Noriyuki Tashima, Daisuke Iwashima, Ken-Ichi Takahashi
Treatment with Sotrovimab and Casirivimab/Imdevimab Enhances Serum SARS-CoV-2 S Antibody Levels in Patients Infected with the SARS-CoV-2 Delta, Omicron BA.1, and BA.5 Variants. Infectious disease reports 14 (6) (2022)
Takahiro Tsuji, Hiroaki Ozasa, Mitsuyoshi Ueda, Shunsuke Aburaya, Tomoko Yamamoto Funazo, Koh Furugaki, Yasushi Yoshimura, Masatoshi Yamazoe, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Hironori Yoshida, Yuichi Sakamori, Hiroaki Wake, Mitsuyoshi Ueda, Young Hak Kim, Toyohiro Hirai
YAP1 mediates survival of ALK-rearranged lung cancer cells treated with alectinib via pro-apoptotic protein regulation. Nature communications 11 (1) (2020)
Yuto Yasuda, Hiroaki Ozasa, Young Hak Kim, Masatoshi Yamazoe, Hitomi Ajimizu, Tomoko Yamamoto Funazo, Takashi Nomizo, Takahiro Tsuji, Hironori Yoshida, Yuichi Sakamori, Naoki Nakajima, Toshi Menju, Akihiko Yoshizawa, Hiroshi Date, Toyohiro Hirai
MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-XL expression. Cell death & disease 11 (3) (2020)
Tomoko Funazo, Takahiro Tsuji, Hiroaki Ozasa, Koh Furugaki, Yasushi Yoshimura, Tetsuya Oguri, Hitomi Ajimizu, Yuto Yasuda, Takashi Nomizo, Yuichi Sakamori, Hironori Yoshida, Young Hak Kim, Toyohiro Hirai
Acquired Resistance to Alectinib in ALK-Rearranged Lung Cancer due to ABCC11/MRP8 Overexpression in a Clinically Paired Resistance Model. Molecular cancer therapeutics 19 (6) (2020)
Tomoko Yamamoto Funazo, Takashi Nomizo, Hiroaki Ozasa, Takahiro Tsuji, Yuto Yasuda, Hironori Yoshida, Yuichi Sakamori, Hiroki Nagai, Toyohiro Hirai, Young Hak Kim
Clinical impact of low serum free T4 in patients with non-small cell lung cancer treated with nivolumab. Scientific reports 9 (1) (2019)